Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

LY75/DEC-205 Protein (AA 28-1666) (His tag)

LY75 Spezies: Human Wirt: HEK-293 Cells Recombinant >90 % as determined by SDS-PAGE.
Produktnummer ABIN6992338
  • Target Alle LY75/DEC-205 (LY75) Proteine anzeigen
    LY75/DEC-205 (LY75) (Lymphocyte Antigen 75 (LY75))
    Protein-Typ
    Recombinant
    Proteineigenschaft
    AA 28-1666
    Spezies
    • 4
    • 3
    • 1
    Human
    Quelle
    • 3
    • 3
    • 2
    HEK-293 Cells
    Aufreinigungstag / Konjugat
    Dieses LY75/DEC-205 Protein ist gelabelt mit His tag.
    Verwendungszweck
    Human LY75 / CD205 Protein, His Tag
    Reinheit
    >90 % as determined by SDS-PAGE.
    Endotoxin-Niveau
    Less than 1.0 EU per μg by the LAL method.
    Top Product
    Discover our top product LY75 Protein
  • Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Lyophilized
    Buffer
    PBS, pH 7.4
    Lagerung
    -20 °C
  • Target
    LY75/DEC-205 (LY75) (Lymphocyte Antigen 75 (LY75))
    Andere Bezeichnung
    LY75 (LY75 Produkte)
    Synonyme
    LY75 Protein, MGC140308 Protein, DEC205 Protein, im:7150926 Protein, si:dkey-78p20.2 Protein, LYT75 Protein, CD205 Protein, DEC-205 Protein, CLEC13B Protein, GP200-MR6 Protein, LY-75 Protein, RGD1565962 Protein, Ly-75 Protein, lymphocyte antigen 75 Protein, CD205 protein Protein, CD302 antigen Protein, LY75 Protein, Cyan7822_2917 Protein, LY5 Protein, ly75 Protein, cd205 Protein, LOC100380704 Protein, LOC100433861 Protein, LOC100483541 Protein, Ly75 Protein
    Hintergrund
    Lymphocyte antigen 75 (Ly 75, also known as CD205, CLEC13B, GP200-MR6 and DEC-205, is a type I transmembrane protein that is primarily expressed on dendritic cells and thymic epithelial cells. LY75 functions as an endocytic receptor for antigens. MEN1309/OBT076, the first antibody drug targeting CD205, has shown strong preclinical anti-tumor activity in lymphoma. After being verified as a single drug in vivo, the antibody-drug conjugate has a synergistic effect with the BCL2 inhibitor Venetoclax and the anti-cd20 monoclonal antibody rituximab.
    Molekulargewicht
    190.7 kDa
    NCBI Accession
    NP_002340
Sie sind hier:
Kundenservice